Market Closed -
Nasdaq
21:30:01 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.2286
USD
|
+2.97%
|
|
-14.57%
|
-47.99%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
19.36
|
23.12
|
46.48
|
170.5
|
84.5
|
39.72
|
Enterprise Value (EV)
1 |
13.4
|
17.69
|
37.71
|
142.9
|
77.14
|
36.27
|
P/E ratio
|
-3.2
x
|
-2.08
x
|
-2.88
x
|
-18.4
x
|
-3.27
x
|
-1.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.44
x
|
15
x
|
47
x
|
11.2
x
|
8,450
x
|
71,562
x
|
EV / Revenue
|
4.46
x
|
11.5
x
|
38.2
x
|
9.41
x
|
7,714
x
|
65,355
x
|
EV / EBITDA
|
-1.24
x
|
-2.32
x
|
-3.39
x
|
-27.9
x
|
-3.37
x
|
-1.63
x
|
EV / FCF
|
-2.33
x
|
-3.63
x
|
-12.9
x
|
113
x
|
-5.51
x
|
-2.48
x
|
FCF Yield
|
-43%
|
-27.5%
|
-7.73%
|
0.88%
|
-18.1%
|
-40.3%
|
Price to Book
|
1.01
x
|
1.63
x
|
3.29
x
|
4.59
x
|
4.53
x
|
3.3
x
|
Nbr of stocks (in thousands)
|
4,841
|
6,217
|
9,460
|
12,962
|
13,876
|
22,803
|
Reference price
2 |
3.999
|
3.720
|
4.913
|
13.15
|
6.090
|
1.742
|
Announcement Date
|
29/08/18
|
28/08/19
|
26/08/20
|
25/08/21
|
28/08/22
|
31/08/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3.004
|
1.54
|
0.9881
|
15.18
|
0.01
|
0.000555
|
EBITDA
1 |
-10.81
|
-7.612
|
-11.11
|
-5.113
|
-22.91
|
-22.28
|
EBIT
1 |
-12.36
|
-8.696
|
-12.19
|
-6.378
|
-24.87
|
-24.15
|
Operating Margin
|
-411.41%
|
-564.64%
|
-1,234.06%
|
-42.01%
|
-248,657.02%
|
-4,350,725.59%
|
Earnings before Tax (EBT)
1 |
-6.344
|
-10.57
|
-12.77
|
-8.906
|
-25.02
|
-20.74
|
Net income
1 |
-6.039
|
-10.27
|
-12.47
|
-8.422
|
-24.65
|
-20.47
|
Net margin
|
-201.03%
|
-666.85%
|
-1,261.75%
|
-55.47%
|
-246,478.15%
|
-3,687,419.82%
|
EPS
2 |
-1.248
|
-1.786
|
-1.707
|
-0.7160
|
-1.861
|
-1.123
|
Free Cash Flow
1 |
-5.757
|
-4.868
|
-2.917
|
1.26
|
-14
|
-14.63
|
FCF margin
|
-191.64%
|
-316.1%
|
-295.19%
|
8.3%
|
-139,980.1%
|
-2,635,182.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/08/18
|
28/08/19
|
26/08/20
|
25/08/21
|
28/08/22
|
31/08/23
|
Fiscal Period: Juni |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
---|
Net sales
1 |
-
|
0.3693
|
0.032
|
15.18
|
0.027
|
0.00011
|
0.00014
|
0.023
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-6.769
|
-6.513
|
0.06
|
-13.26
|
-11.68
|
-
|
-10.49
|
Operating Margin
|
-
|
-1,832.75%
|
-20,358.42%
|
0.4%
|
-49,218.07%
|
-10,615,918.18%
|
-
|
-45,657.9%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-11.68
|
-
|
-
|
Net income
1 |
-5.881
|
-
|
-
|
-
|
-
|
-11.63
|
-13.59
|
-6.879
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-10,568,554.55%
|
-9,704,307.14%
|
-29,948.41%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-0.8746
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/02/20
|
26/08/20
|
24/02/21
|
25/08/21
|
23/02/22
|
28/08/22
|
28/02/23
|
31/08/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5.96
|
5.43
|
8.76
|
27.6
|
7.36
|
3.44
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-5.76
|
-4.87
|
-2.92
|
1.26
|
-14
|
-14.6
|
ROE (net income / shareholders' equity)
|
-27.1%
|
-61.4%
|
-88%
|
-32.4%
|
-87.3%
|
-135%
|
ROA (Net income/ Total Assets)
|
-24.1%
|
-22%
|
-34.5%
|
-9.82%
|
-33.4%
|
-47.2%
|
Assets
1 |
25.05
|
46.63
|
36.19
|
85.72
|
73.78
|
43.38
|
Book Value Per Share
2 |
3.970
|
2.280
|
1.490
|
2.870
|
1.340
|
0.5300
|
Cash Flow per Share
2 |
1.230
|
0.8700
|
0.9300
|
2.090
|
0.5300
|
0.2300
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/08/18
|
28/08/19
|
26/08/20
|
25/08/21
|
28/08/22
|
31/08/23
|
|
1st Jan change
|
Capi.
|
---|
| -47.99% | 6.81M | | +38.65% | 39.36B | | -8.62% | 38.52B | | +26.95% | 30.74B | | +10.74% | 25.92B | | -13.50% | 26.03B | | +44.87% | 14.13B | | +34.36% | 12.73B | | -7.14% | 11.29B | | -12.61% | 10.64B |
Other Biotechnology & Medical Research
|